CD274 and neoplasm: Pembrolizumab, an anti-PD-1 antibody, was active in pretreated esophageal cancer patients with PD-L1 expressing tumors (> 1% PD-L1 positive tumor cells and/or tumor stroma), with a partial response (PR) rate of 30.4% (67).